Research Analyst at LifeSci Capital
Anshul Dhankher is an Equity Research Analyst at LifeSci Capital, specializing in coverage of biopharmaceutical and emerging life sciences companies, including firms such as Perspective Therapeutics and Aura Biosciences. He has issued 15 stock ratings with a coverage focus on US markets, holding a strong bias toward Buy ratings and notable recommendations like a Buy on Aura Biosciences which yielded a return of +38.5%. Dhankher began his professional career in operations at AbbVie before transitioning to equity research, bringing both corporate and analytical perspectives when he joined LifeSci Capital. Holding a PhD and other professional credentials, he is active in fundamental research and regularly participates in earnings calls and sector analysis.
Anshul Dhankher of LifeSci Capital questioned whether Rain Oncology is targeting a specific 'sweet spot' in terms of development stage or deal structure for potential in-licensing opportunities.
CEO Avanish Vellanki responded that the company's primary focus is on clinical-stage assets to leverage the demonstrated expertise of its clinical organization, but he did not provide further specifics on deal structures or other criteria.
Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.
Trusted by leading investment firms and analysts